[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cpsp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cpsp":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100493713","neuromodulation-for-central-post-stroke-pain-mechanism-safety-and-outcome-100493713",false,"NCT05708729","Neuromodulation for Central Post-stroke Pain: Mechanism, Safety and Outcome","Inclusion Criteria:\n\n1. Able to provide voluntary written informed consent of the participant prior to any screening procedures\n2. Male or female patients\n3. Aged 18-70 years\n4. Diagnosed with definite CPSP (Treede-Klit criteria) (1, 9), which is pharmacorefractory (i.e. amitriptyline 75mg\u002Fd 4w, lamotrigine 200mg\u002Fd 8w and pregabalin 600mg\u002Fd resulting in \\\u003C50% VAS reduction and\u002For intolerable side-effects)\n\nExclusion Criteria:\n\n1. Aphasia\n2. Pregnancy or intention to become pregnant in the following year\n3. Medical inoperability\n4. Impossibility to temporarily withhold anticoagulation or anti-platelet medication\n5. Impossibility to undergo MRI, fMRI and\u002For PET imaging\n6. Complete destruction of the stimulation target region (M1 or Vc)\n7. Uncontrolled seizures\n8. Expected relocation in the following year.","ALL","18 Years","70 Years",{"count":19,"type":20},32,"ESTIMATED","INTERVENTIONAL",[23],"NA","Central post-stroke pain (CPSP) is an often pharmacorefractory type of neuropathic pain that develops in 8% of stroke patients. CPSP has been treated with three distinct types of neuromodulation (deep brain stimulation of the sensory thalamus (Vc-DBS), motor cortex repetitive transcranial magnetic stimulation (M1-rTMS), and motor cortex stimulation (MCS)), but the level of evidence for these procedures is very low. Moreover, data on the changes in pain brain circuitry in CPSP, and the effect of neuromodulation on this circuitry is very limited.",[26,27],"Central Post-stroke Pain","CPSP",[29,30,31,32],"neuromodulation","DBS","rTMS","MCS","RECRUITING","2024-06-28",{"date":36,"type":37},"2024-07-01","ACTUAL",{"date":39,"type":37},"2023-01-24",{"date":41,"type":20},"2026-04",{"name":43,"class":44},"Universitaire Ziekenhuizen KU Leuven","OTHER"]